A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial
Sandra Korol(Montreal Heart Institute), Simon de Denus(Montreal Heart Institute), Mark Liszkowski(Montreal Heart Institute), Anique Ducharme(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Michel White(Montreal Heart Institute), Paul‐Eduard Neagoe(Montreal Heart Institute), Martin G. Sirois(Montreal Heart Institute), Martin Jutras(Université de Montréal), Diana Chaar(Montreal Heart Institute), Grégoire Leclair(Université de Montréal), Mathieu Bernier, Jean‐Lucien Rouleau(Montreal Heart Institute), Asmaa Mansour(Montreal Heart Institute), François Tournoux(Centre Hospitalier de l’Université de Montréal), Joël Lavoie(Montreal Heart Institute), Marie‐Claude Guertin
Cited by 17
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
|New England Journal of Medicine|2004|1.9k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k